Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Millennium restructuring

MLNM plans to reduce its headcount by 600 to 1,700 from 2,300 by the end of 2004 in order to focus on

Read the full 221 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE